Orforglipron: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store at controlled room temperature. Specific storage requirements will be defined in the prescribing information upon regulatory approval. As an oral capsule, orforglipron does not require refrigeration (unlike injectable GLP-1 agonists).
Protocol Quick-Reference
Weight management in adults with obesity or overweight
Dosing
Amount
6 mg, 12 mg, or 36 mg
Frequency
Once daily
Duration
72 weeks (Phase 3)
Administration
Route
OralTiming
Taken once daily as an oral capsule; no food or water restrictions required; dose escalation used to minimize GI side effects
Cycle
Duration
Ongoing (long-term use intended)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
Fasting glucose and HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk markers
Fasting glucose and HbA1c
When: 12 weeks
Why: Monitor glycemic changes
Lipid panel
When: 24 weeks
Why: Assess metabolic improvements
๐ก Key Considerations
- โInvestigational: not yet FDA-approved; regulatory submissions initiated in 2025
- โNon-peptide small molecule; not a traditional peptide despite targeting the GLP-1 receptor
- โDose escalation from lower to higher doses is used to minimize gastrointestinal side effects (nausea, diarrhea, vomiting)
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Obesity / Weight Management (ATTAIN-1 trial protocol) | Once-daily oral capsule. Doses studied: 6 mg, 12 mg, and 36 mg. Dose escalation schedule used in clinical trials to reach target dose. 36 mg dose achieved greatest weight loss (11.2% at 72 weeks). | Once daily oral administration | 72 weeks in Phase 3 trials; intended for long-term use | Orforglipron is taken once daily without food or water restrictions. Dose escalation from lower to higher doses is used to minimize gastrointestinal side effects. Not yet FDA-approved. |
| Type 2 Diabetes with Obesity (ATTAIN-2 trial protocol) | Once-daily oral capsule. Doses studied: 6 mg, 12 mg, and 36 mg. 36 mg dose achieved 9.6% weight loss and 1.8% HbA1c reduction. | Once daily oral administration | 72 weeks in Phase 3 trial | Patients had baseline HbA1c of 8.1%. All doses produced significant glycemic improvement. HbA1c reductions ranged from 1.3% to 1.8% across dose groups. |
| Type 2 Diabetes (ACHIEVE-1 trial protocol) | Once-daily oral capsule at 3 mg, 12 mg, or 36 mg. All doses produced significant HbA1c reductions versus placebo. | Once daily oral administration | 40 weeks in Phase 3 trial | Studied as add-on to metformin in early type 2 diabetes. HbA1c reductions were significant at all dose levels. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Not applicable. Orforglipron is an oral capsule formulation that does not require reconstitution, mixing, or dilution. Capsules are taken whole by mouth.
๐งStorage Requirements
Store at controlled room temperature. Specific storage requirements will be defined in the prescribing information upon regulatory approval. As an oral capsule, orforglipron does not require refrigeration (unlike injectable GLP-1 agonists).
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Orforglipron is an investigational medication that has not yet received FDA approval. All dosing information presented here is derived from published clinical trial protocols and results. Dosing should only occur under the supervision of qualified healthcare providers, ideally within the context of clinical trials.
Clinical Trial Dosing#
Dose Levels Studied#
Orforglipron has been evaluated at multiple dose levels across Phase 2 and Phase 3 trials:
| Trial | Doses Studied | Duration | Population |
|---|---|---|---|
| Phase 2 (Obesity) | 12, 24, 36, 45 mg | 36 weeks | Adults with obesity/overweight |
| ATTAIN-1 (Phase 3) | 6, 12, 36 mg | 72 weeks | Adults with obesity |
| ATTAIN-2 (Phase 3) | 6, 12, 36 mg | 72 weeks | Adults with obesity + T2D |
| ACHIEVE-1 (Phase 3) | 3, 12, 36 mg | 40 weeks | Adults with T2D |
The 36 mg dose has consistently demonstrated the greatest efficacy for both weight loss and glycemic control across all trials.
Dose Escalation#
All clinical trials employed a gradual dose escalation protocol to minimize gastrointestinal adverse events. While the exact titration schedule has not been fully published for all trials, the approach involves:
- Starting at a low dose
- Gradual weekly or biweekly increases
- Reaching the target maintenance dose over several weeks
This approach is consistent with all GLP-1 receptor agonist therapies, where gradual titration reduces the incidence and severity of nausea and vomiting during initiation.
Efficacy by Dose#
Weight Loss (ATTAIN-1, 72 weeks):
| Dose | Mean Weight Loss | Achieving 10%+ Loss | Achieving 15%+ Loss |
|---|---|---|---|
| 6 mg | 7.5% | 29.9% | 15.7% |
| 12 mg | 8.4% | 34.4% | 18.2% |
| 36 mg | 11.2% | 54.6% | 36.0% |
| Placebo | 2.1% | 12.9% | 5.9% |
HbA1c Reduction (ATTAIN-2, 72 weeks):
All orforglipron doses produced HbA1c reductions of 1.3-1.8% from a baseline of 8.1%, demonstrating significant glycemic improvement in patients with type 2 diabetes.
Administration#
Oral Dosing#
Orforglipron is administered as a once-daily oral capsule. A major practical advantage over oral semaglutide (Rybelsus) is the absence of food and water restrictions:
- Rybelsus: Must be taken on empty stomach with no more than 4 oz water, 30 minutes before food
- Orforglipron: Can be taken at any time without meal timing restrictions
This convenience advantage may improve long-term adherence compared to oral semaglutide.
Timing#
In clinical trials, orforglipron was administered once daily in the morning. However, the absence of food restrictions provides flexibility in dosing timing. The long half-life (25-68 hours at steady state) ensures stable plasma levels even with some variability in dosing time.
Missed Doses#
Specific missed dose guidance has not been published from the ATTAIN program. Given the once-daily dosing and accumulation-extended half-life, a single missed dose would be expected to have less impact on plasma levels than a missed dose of a shorter-acting agent.
Storage#
As an oral capsule formulation, orforglipron is expected to be stored at controlled room temperature, a significant practical advantage over injectable GLP-1 agonists that require refrigeration. Specific storage conditions will be defined in the prescribing information upon regulatory approval.
Special Considerations#
Oral-Only Administration#
Unlike semaglutide (available as both injectable and oral) and tirzepatide (injectable only), orforglipron is being developed exclusively as an oral formulation. This positions it as a potential first-line option for patients who prefer oral medication over injection.
No Reconstitution Required#
As a pre-formed oral capsule, orforglipron requires no reconstitution, dilution, or device preparation. This simplicity contrasts with injectable GLP-1 agonists that require pen devices and subcutaneous injection technique.
Dose-Response Relationship#
A clear dose-response relationship has been established across trials, with the 36 mg dose consistently showing the greatest efficacy. The 6 mg and 12 mg doses provide intermediate levels of weight loss and glycemic control, which may be relevant for patients who do not tolerate the full dose.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Orforglipron
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.